Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999902 | 0.85 | DYRK1A (0.53) | DYRK1ADYRK1BGAAMTORNPC1 | |
| SCHEMBL5695258 | 0.79 | GAA (0.67) | GAANPC1RAB9AMAPTNPSR1 | |
| SCHEMBL1998129 | 0.78 | MTOR (0.67) | DYRK1ADYRK1BGAAMTORNPC1 | |
| SCHEMBL16318400 | 0.78 | GAA (0.55) | GAAMTORNPC1RAB9AMAPT | |
| SCHEMBL1998475 | 0.77 | AKR1C3 (0.59) | DYRK1ADYRK1BMTORMEN1KMT2A | |
| SCHEMBL1998478 | 0.77 | KDR (0.63) | MTORNPC1RAB9AMAPTTP53 | |
| SCHEMBL1163657 | 0.77 | MEN1 (0.56) | DYRK1ADYRK1BGAAMTORNPC1 | |
| Trifluoroacetic Acid SCHEMBL6501025 | 0.76 | GAA (0.52) | GAAMTORNPC1RAB9AMAPT | |
| SCHEMBL5695215 | 0.75 | GAA (0.61) | GAAMTORNPC1RAB9AMAPT | |
| SCHEMBL14063636 | 0.74 | DYRK1A (0.50) | DYRK1ADYRK1BGAAMTORADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076106-A1 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | US | claimed |
| US-20210338680-A1 | METHODS RELATED TO OPIOID THERAPEUTICS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2021-11-04 | — | — | US | disclosed |
| US-7960561-B2 | 2-(phenylamino) benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels | NEUROSEARCH A/S (DK) | 2011-06-14 | — | — | US | disclosed |
| US-20090076106-A1 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels | NEUROSEARCH A/S (DK) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076106-A1 | 2-(Phenylamino) Benzimidazole Derivatives and Their Use as Modulators of Small- Conductance Calcuim-Activated Potassium Channels | KCNN2, KCNN1, KCNN3 | DYRK1A 2775/4885DYRK1B 2640/4885GAA 2861/4885 |
| US-20210338680-A1 | METHODS RELATED TO OPIOID THERAPEUTICS | OPRL1, OPRK1, GPR139 | DYRK1A 2117/4885DYRK1B 2259/4885GAA 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.